Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Michael Ryan is an EIR at RA Capital. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Fuad Naser is a Senior Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky, RA Capital's founder and managing partner. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Prior to RA Capital, he represented emerging companies and venture capital investment funds at two international law firms. Scott brings to RAVen 20 years of experience working with clients and portfolio companies to complete transactions including multiple IPOs and acquisitions of portfolio companies. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Gabes primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. He previously served as the CFO of Research Alliance Corp I before its merger with Point Biopharma and served on the boards of Research Alliance Corp I and Research Alliance Corp II. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . Michael holds a B.S. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. He continues advising both in a consultant capacity. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Peter Kolchinsky, Research Alliance Corp II: Profile and Biography RA Capital makes no guarantees as to their accuracy or completeness. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Brendan has more than 18 years of experience as a tax professional. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Emily Greenis a Visual Identity Designer at RA Capital Management. Ernesto Gonzalez is a Business Systems Manager at RA Capital. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Support. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. James Schneider is the Deputy General Counsel at RA Capital Management. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. He is also an Advisor to HotSpot Therapeutics and recently served on the Board of Directors at Research Alliance Corporation I (merged with POINT Biopharma) and at TetraGenetics (acquired by AbCellera). Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Prior to Evotec, Cony worked at IGEN, where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fundraising. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Jessica Sagers is Head of Engagement at RA Capital Management. Michael Sherman is a Venture Partner at RA Ventures. Cameron is a Senior Research Assistant at RA Capital Management. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Milind attended the residential Executive Program at The Wharton School of Management. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Peter Kolchinsky Net Worth (2023) | wallmine Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Asia Pacific +65 6212 1000. Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies.